2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Movement Disorders in 1 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, XQ | 1 |
| Kong, XC | 1 |
| Qian, C | 1 |
| Zhang, D | 1 |
1 other study available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Movement Disorders
| Article | Year |
|---|---|
FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models.
Topics: Adaptor Proteins, Signal Transducing; alpha-Synuclein; Animals; Benzeneacetamides; Blotting, Western | 2012 |